Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05563688
Other study ID # 2021PBMD09
Secondary ID 2022-A00464-39
Status Recruiting
Phase
First received
Last updated
Start date October 26, 2022
Est. completion date June 2024

Study information

Verified date November 2022
Source Direction Centrale du Service de Santé des Armées
Contact Pierre FABRIES, MD
Phone 178652089
Email pierre.fabries@intradef.gouv.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

At altitude, humans are exposed to environmental hypoxia induced by the decrease in barometric pressure. On duty or in training, mountain troops, paratroopers or aircrew are regularly exposed to altitude. The effects of altitude on humans occur gradually from 1500 m and depend on both the duration of exposure and the altitude level. Cognitive disorders can occur from 3500 m (threshold of disorders) but there is a very large inter-individual variability. The countermeasure to altitude hypoxia is oxygen but its use is not systematic between 3000 and 4000 m. Its use depends on the duration of exposure, without clearly established standards. Incapacitating effects on the operational capacity and health of soldiers can therefore occur as early as 3500 m. In operations or during training, altitude exposure is often associated with a significant sleep debt (particularly during night or early morning missions), jet lag or precarious rest conditions in overseas operations. These sleep restrictions promote the degradation of mental performance with effects similar to those observed in hypoxia. The combination of these constraints induces a physiological stress which can favour alterations in mental performance, an increase in incapacity, intolerance to altitude or the occurrence of altitude-related pathologies in military personnel. This could occur in particular in the operational zone around the threshold of disorders (3500 m) where the indication of oxygen is discussed. The objective of this study is to assess the impact of acute sleep restriction on hypoxia tolerance.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Male - Healthy - Between 18 and 45 - Smoking < 5 cigarettes per day or nicotine-free electronic cigarette - Having regular physical activity (between 1 and 4 hours of physical activity per week) - Affiliated or entitled to a social security plan - No contraindication to physical exercise - Having given their consent Exclusion Criteria: - Female - BMI > 30 - Active medical pathology (cardiological, renal, hepatic, cutaneous, neurological, etc.), - History of active pathology of less than 6 months - Significant deviation with the normal values observed during the interrogation, clinical examination or electrocardiogram - Having spent time at altitude (> 3500 m) during the last 3 months - Absolute or relative contraindication to a stay at high altitude - Medical contraindication to sport practice - Skin allergy to modified ethanol or capsaicin - Wearing a pacemaker or ferromagnetic implants - Poor venous capital - Pittsburgh Sleep Quality Index Questionnaire > 5 - Usual sleep duration < 6 hours - Not covered by a health insurance plan

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Hypoxia exposure
Each participant will be exposed to the hypoxic environment on 2 occasions (one after a normal sleep night and one after sleep deprivation). Each exposure will be for 5 hours at a FiO2 of 13.2% (3500 m simulated altitude). This exposure will be carried out in a normobaric hypoxic tent (Sporting Edge®).
Sleep deprivation
Each participant will be exposed to sleep deprivation on 2 occasions (one before normoxia exposure and one before hypoxia exposure). Each sleep deprivation involves a time spent in bed of 3 hours (03h00 - 06h00). Sleep deprivation will be carried out in a sleep apartment. Sleep duration and quality will be assessed using a sleep headband (Dreem®), actigraphs Actiwatch® and E4 Empatica®) and a sleep diary.
Behavioral:
Cognitive tasks
Participants will perform several cognitive tasks in the following conditions: in normoxia (FiO2 = 21%) after a night of usual sleep (> 6 hours) ; in normoxia (FiO2 = 21%) after a night of reduced sleep (3 hours); in normobaric hypoxia (FiO2 = 13.2%) after a night of normal sleep (> 6 hours); in normobaric hypoxia (FiO2 = 13.2%) after a night of reduced sleep (3 hours).

Locations

Country Name City State
France Institut de Recherche Biomédicale des Armées Brétigny-sur-Orge

Sponsors (1)

Lead Sponsor Collaborator
Direction Centrale du Service de Santé des Armées

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean reaction time (in ms) to the 10-minute psychomotor vigilance task (PVT-10), at the end of the exposure. PVT-10 is a sustained-attention, reaction-timed task that measures the consistency with which subjects respond to a visual stimulus.
The participant sits in front of a computer. He has a screen in front of him with a 4-digit counter (0 at the start). He is instructed to click the left mouse button as fast as possible when the counter starts to scroll. The counter returns to zero when the participant has clicked.
Reaction time (in ms) is calculated for each stimulus.
Through study completion (20.5 months)
See also
  Status Clinical Trial Phase
Recruiting NCT04498598 - Structural Modification In Supraglottic Airway Device N/A
Completed NCT05532670 - N600X Low Saturation Accuracy Validation
Enrolling by invitation NCT04106401 - Intravascular Volumes in Hypoxia During Antarctic Confinement N/A
Recruiting NCT05883137 - High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
Not yet recruiting NCT05817448 - Hypoxia-induced Autophagy in the Pathogenesis of MAP
Recruiting NCT02661152 - DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. Phase 3
Terminated NCT02801162 - Evaluation of Accuracy and Precision of a New Arterial Blood Gas Analysis System Blood in Comparison With the Reference Standard N/A
Not yet recruiting NCT02201875 - Intrinsic Periodic Pattern of Breathing N/A
Completed NCT02943863 - Regional Ventilation During High Flow Nasal Cannula and Conventional Nasal Cannula in Patients With Hypoxia N/A
Completed NCT02105298 - Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study) N/A
Completed NCT01922401 - Inverse Ratio Ventilation on Bariatric Operation N/A
Active, not recruiting NCT01681238 - Goal-directed Therapy in High-risk Surgery N/A
Completed NCT01463527 - Using Capnography to Reduce Hypoxia During Pediatric Sedation N/A
Completed NCT01507623 - Value of Capnography During Nurse Administered Propofol Sedation (NAPS) N/A
Withdrawn NCT00638040 - The Gene Expression Studies of the Role of Tumor Microenvironments in Tumor Progression N/A
Active, not recruiting NCT06097754 - Intermittent Exogenous Ketosis (IEK) at High Altitude N/A
Completed NCT04589923 - The VISION-Acute Study
Completed NCT05044585 - Evaluation of RDS MultiSense® in Desaturation Analysis in Healthy Volunteers N/A
Completed NCT03659513 - The Effect of ECMO on the Pharmacokinetics of the Drugs and Their Clinical Efficacy
Completed NCT03221387 - Sleep and Daytime Use of Humidified Nasal High-flow Oxygen in COPD Outpatients N/A